$15.82
+0.37
(+2.39%)▲
Insights on Bausch + Lomb Corp.
Revenue is down for the last 2 quarters, 1.03B → 1.00B (in $), with an average decrease of 2.7% per quarter
Netprofit is down for the last 2 quarters, -32.0M → -84.0M (in $), with an average decrease of 162.5% per quarter
In the last 1 year, West Pharmaceutical Services Inc has given 44.0% return, outperforming this stock by 44.2%
4.8%
Downside
Day's Volatility :5.04%
Upside
0.25%
9.17%
Downside
52 Weeks Volatility :34.53%
Upside
27.93%
Period | Bausch + Lomb Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -13.54% | -1.3% | 0.0% |
6 Months | -16.12% | 1.2% | 0.0% |
1 Year | 1.58% | -5.7% | -6.5% |
3 Years | -22.75% | 17.1% | -6.5% |
Market Capitalization | 5.4B |
Book Value | $19.43 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.59 |
PEG Ratio | 2.57 |
Wall Street Target Price | 29.37 |
Profit Margin | -5.22% |
Operating Margin TTM | 6.75% |
Return On Assets TTM | 1.04% |
Return On Equity TTM | -2.88% |
Revenue TTM | 4.0B |
Revenue Per Share TTM | 11.33 |
Quarterly Revenue Growth YOY | 6.9% |
Gross Profit TTM | 2.2B |
EBITDA | 556.0M |
Diluted Eps TTM | -0.59 |
Quarterly Earnings Growth YOY | -0.89 |
EPS Estimate Current Year | 0.92 |
EPS Estimate Next Year | 0.92 |
EPS Estimate Current Quarter | 0.26 |
EPS Estimate Next Quarter | 0.34 |
What analysts predicted
Upside of 85.65%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | - |
Net Income | 710.0M | - |
Net Profit Margin | 19.37% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 3.08% |
Net Income | 298.0M | ↓ 58.03% |
Net Profit Margin | 7.89% | ↓ 11.48% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↓ 9.69% |
Net Income | -17.0M | ↓ 105.7% |
Net Profit Margin | -0.5% | ↓ 8.39% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 10.35% |
Net Income | 182.0M | ↓ 1170.59% |
Net Profit Margin | 4.83% | ↑ 5.33% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 0.08% |
Net Income | 15.0M | ↓ 91.76% |
Net Profit Margin | 0.4% | ↓ 4.43% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 941.0M | ↑ 5.85% |
Net Income | 7.0M | ↓ 65.0% |
Net Profit Margin | 0.74% | ↓ 1.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 942.0M | ↑ 0.11% |
Net Income | -15.0M | ↓ 314.29% |
Net Profit Margin | -1.59% | ↓ 2.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 996.0M | ↑ 5.73% |
Net Income | -1000.0K | ↓ 93.33% |
Net Profit Margin | -0.1% | ↑ 1.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 931.0M | ↓ 6.53% |
Net Income | -88.0M | ↑ 8700.0% |
Net Profit Margin | -9.45% | ↓ 9.35% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 11.17% |
Net Income | -32.0M | ↓ 63.64% |
Net Profit Margin | -3.09% | ↑ 6.36% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 2.71% |
Net Income | -84.0M | ↑ 162.5% |
Net Profit Margin | -8.34% | ↓ 5.25% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | - |
Total Liabilities | 1.4B | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.3B | ↓ 1.76% |
Total Liabilities | 1.3B | ↓ 11.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↓ 3.93% |
Total Liabilities | 1.4B | ↑ 11.19% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 11.1B | ↑ 2.97% |
Total Liabilities | 4.0B | ↑ 184.52% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 0.87% |
Total Liabilities | 4.0B | ↑ 9.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.7B | ↓ 2.78% |
Total Liabilities | 3.9B | ↓ 3.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.1B | ↑ 4.19% |
Total Liabilities | 4.0B | ↑ 3.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.2B | ↑ 0.22% |
Total Liabilities | 4.1B | ↑ 1.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.3B | ↑ 1.31% |
Total Liabilities | 4.3B | ↑ 4.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.1B | ↑ 15.49% |
Total Liabilities | 6.2B | ↑ 44.34% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 763.0M | - |
Investing Cash Flow | -74.0M | - |
Financing Cash Flow | -665.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 799.0M | ↑ 4.72% |
Investing Cash Flow | -186.0M | ↑ 151.35% |
Financing Cash Flow | -606.0M | ↓ 8.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 522.0M | ↓ 34.67% |
Investing Cash Flow | -256.0M | ↑ 37.63% |
Financing Cash Flow | -232.0M | ↓ 61.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 873.0M | ↑ 67.24% |
Investing Cash Flow | -214.0M | ↓ 16.41% |
Financing Cash Flow | -712.0M | ↑ 206.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 345.0M | ↓ 60.48% |
Investing Cash Flow | -215.0M | ↑ 0.47% |
Financing Cash Flow | 81.0M | ↓ 111.38% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0M | ↓ 98.15% |
Investing Cash Flow | -41.0M | ↓ 49.38% |
Financing Cash Flow | 52.0M | ↓ 240.54% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 156.0M | ↑ 5100.0% |
Investing Cash Flow | -35.0M | ↓ 14.63% |
Financing Cash Flow | 145.0M | ↑ 178.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.0M | ↓ 82.69% |
Investing Cash Flow | -49.0M | ↑ 40.0% |
Financing Cash Flow | -109.0M | ↓ 175.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 159.0M | ↑ 488.89% |
Investing Cash Flow | -90.0M | ↑ 83.67% |
Financing Cash Flow | -7.0M | ↓ 93.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -56.0M | ↓ 135.22% |
Investing Cash Flow | -64.0M | ↓ 28.89% |
Financing Cash Flow | 91.0M | ↓ 1400.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.0M | ↓ 57.14% |
Investing Cash Flow | -28.0M | ↓ 56.25% |
Financing Cash Flow | 90.0M | ↓ 1.1% |
Sell
Neutral
Buy
Bausch + Lomb Corp. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bausch + Lomb Corp. | -6.98% | -16.12% | 1.58% | -22.75% | -22.75% |
![]() Intuitive Surgical, Inc. | 13.68% | -0.72% | 16.86% | 21.18% | 82.26% |
![]() Resmed Inc. | 3.74% | -28.13% | -27.22% | -23.87% | 42.37% |
![]() Becton, Dickinson And Company | -8.05% | -6.2% | -3.23% | -1.86% | -2.72% |
![]() West Pharmaceutical Services Inc | 5.63% | 2.44% | 46.92% | 29.55% | 222.0% |
![]() Alcon Ag | 2.56% | -4.35% | 11.05% | 19.39% | 30.69% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bausch + Lomb Corp. | 914.0 | NA | 2.57 | 0.92 | -0.03 | 0.01 | 0.0 | 19.43 |
![]() Intuitive Surgical, Inc. | 74.65 | 74.65 | 3.27 | 5.59 | 0.13 | 0.08 | 0.0 | 35.62 |
![]() Resmed Inc. | 24.98 | 24.98 | 1.74 | 6.52 | 0.24 | 0.12 | 0.01 | 28.9 |
![]() Becton, Dickinson And Company | 46.93 | 46.93 | 2.31 | 12.22 | 0.06 | 0.03 | 0.02 | 88.83 |
![]() West Pharmaceutical Services Inc | 47.61 | 47.61 | 4.06 | 7.99 | 0.21 | 0.13 | 0.0 | 38.76 |
![]() Alcon Ag | 80.48 | 80.48 | NA | 2.72 | 0.02 | 0.02 | 0.0 | 40.86 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bausch + Lomb Corp. | Buy | $5.4B | -22.75% | 914.0 | -5.22% |
![]() Intuitive Surgical, Inc. | Buy | $112.0B | 82.26% | 74.65 | 22.14% |
![]() Resmed Inc. | Buy | $22.6B | 42.37% | 24.98 | 20.72% |
![]() Becton, Dickinson And Company | Buy | $69.3B | -2.72% | 46.93 | 7.66% |
![]() West Pharmaceutical Services Inc | Buy | $26.1B | 222.0% | 47.61 | 19.12% |
![]() Alcon Ag | Buy | $36.0B | 30.69% | 80.48 | 4.85% |
Fidelity International Ltd
Goldentree Asset Management LP
Eminence Capital LLC
BlackRock Inc
ICAHN CARL C
Maple Rock Capital Partners, Inc.
bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Organization | Bausch + Lomb Corp. |
Employees | 13000 |
CEO | Mr. Joseph C. Papa |
Industry | Healthcare |